237 related articles for article (PubMed ID: 31719146)
1. Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugs.
Zhang W; Yang Y; Dong Z; Shi Z; Zhang JT
J Biol Chem; 2019 Dec; 294(52):20222-20232. PubMed ID: 31719146
[TBL] [Abstract][Full Text] [Related]
2. The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.
Macalou S; Robey RW; Jabor Gozzi G; Shukla S; Grosjean I; Hegedus T; Ambudkar SV; Bates SE; Di Pietro A
Cell Mol Life Sci; 2016 May; 73(9):1927-37. PubMed ID: 26708291
[TBL] [Abstract][Full Text] [Related]
3. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
Han B; Zhang JT
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
[TBL] [Abstract][Full Text] [Related]
5. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
6. The ABCG2 multidrug transporter is a pump gated by a valve and an extracellular lid.
Khunweeraphong N; Szöllősi D; Stockner T; Kuchler K
Nat Commun; 2019 Nov; 10(1):5433. PubMed ID: 31780715
[TBL] [Abstract][Full Text] [Related]
7. The ABCG2/BCRP transporter and its variants - from structure to pathology.
Sarkadi B; Homolya L; Hegedűs T
FEBS Lett; 2020 Dec; 594(23):4012-4034. PubMed ID: 33015850
[TBL] [Abstract][Full Text] [Related]
8. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
9. Residues contributing to drug transport by ABCG2 are localised to multiple drug-binding pockets.
Cox MH; Kapoor P; Briggs DA; Kerr ID
Biochem J; 2018 May; 475(9):1553-1567. PubMed ID: 29661915
[TBL] [Abstract][Full Text] [Related]
10. Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport.
Hou YX; Li CZ; Palaniyandi K; Magtibay PM; Homolya L; Sarkadi B; Chang XB
Biochemistry; 2009 Sep; 48(38):9122-31. PubMed ID: 19691360
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
12. Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2.
Sjöstedt N; van den Heuvel JJMW; Koenderink JB; Kidron H
Pharm Res; 2017 Aug; 34(8):1626-1636. PubMed ID: 28281205
[TBL] [Abstract][Full Text] [Related]
13. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
Henriksen U; Gether U; Litman T
J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
[TBL] [Abstract][Full Text] [Related]
14. Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.
Inoue Y; Morita T; Onozuka M; Saito KI; Sano K; Hanada K; Kondo M; Nakamura Y; Kishino T; Nakagawa H; Ikegami Y
Cells; 2019 Jul; 8(7):. PubMed ID: 31340525
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.
Polgar O; Ierano C; Tamaki A; Stanley B; Ward Y; Xia D; Tarasova N; Robey RW; Bates SE
Biochemistry; 2010 Mar; 49(10):2235-45. PubMed ID: 20088606
[TBL] [Abstract][Full Text] [Related]
16. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
17. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells.
Wu ZX; Mai Q; Yang Y; Wang JQ; Ma H; Zeng L; Chen ZS; Pan Y
Biomed Pharmacother; 2021 Apr; 136():111223. PubMed ID: 33450491
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]